Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
69 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Secondary Hyperparathyroidism - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Secondary Hyperparathyroidism - Pipeline Review, H2 2014', provides an overview of the Secondary Hyperparathyroidism's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Secondary Hyperparathyroidism and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Secondary Hyperparathyroidism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Secondary Hyperparathyroidism pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Secondary Hyperparathyroidism Overview 7 Therapeutics Development 8 Pipeline Products for Secondary Hyperparathyroidism - Overview 8 Pipeline Products for Secondary Hyperparathyroidism - Comparative Analysis 9 Secondary Hyperparathyroidism - Therapeutics under Development by Companies 10 Secondary Hyperparathyroidism - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Secondary Hyperparathyroidism - Products under Development by Companies 14 Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development 15 Amgen Inc. 15 Nektar Therapeutics 16 Astellas Pharma Inc. 17 Mitsubishi Tanabe Pharma Corporation 18 OPKO Health, Inc. 19 NPS Pharmaceuticals, Inc. 20 Deltanoid Pharmaceuticals Inc. 21 Secondary Hyperparathyroidism - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 cinacalcet hydrochloride - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 velcalcetide - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 calcifediol MR - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 lunacalcipol - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 CTAP-201 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 DP-001 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 ASP-7991 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 MT-4580 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 CARD-024 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 NKTR-228 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 VS-105 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 VS-110 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 CTA-091 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Calcimimetic-18 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 VS-411 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Secondary Hyperparathyroidism - Recent Pipeline Updates 52 Secondary Hyperparathyroidism - Dormant Projects 60 Secondary Hyperparathyroidism - Product Development Milestones 61 Featured News & Press Releases 61 Aug 29, 2014: Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan 61 Aug 18, 2014: Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis 61 Aug 11, 2014: Rayaldee Phase 3 Trial Meets Primary Endpoints 62 Aug 07, 2014: OPKO Submits IND for Rayaldee as Adjunctive Cancer Therapy 63 Jul 22, 2014: OPKO Granted Patent from US Patent & Trademark Office for RAYALDEE 64 Dec 19, 2013: OPKO Completes Patient Recruitment in Second Phase 3 Trial of Rayaldy 64 Aug 15, 2013: OPKO Surpasses 50% Enrollment in Second Phase 3 Trial of Rayaldy 65 Jun 27, 2013: Kyowa Hakko Kirin Files Application Seeking Approval For Additional Indication For Regpara Tablets 25mg And 75mg 66 May 23, 2013: Opko Health Surpasses 50% Enrollment In First Phase III Trial Of Rayaldy For Treatment Of Secondary Hyperparathyroidism 66 Mar 07, 2013: Health Canada Cautions Against Use Of Amgen's Sensipar In Children 67 Appendix 68 Methodology 68 Coverage 68 Secondary Research 68 Primary Research 68 Expert Panel Validation 68 Contact Us 69 Disclaimer 69
List of Tables Number of Products under Development for Secondary Hyperparathyroidism, H2 2014 8 Number of Products under Development for Secondary Hyperparathyroidism - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Comparative Analysis by Late Stage Development, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Secondary Hyperparathyroidism - Pipeline by Amgen Inc., H2 2014 15 Secondary Hyperparathyroidism - Pipeline by Nektar Therapeutics, H2 2014 16 Secondary Hyperparathyroidism - Pipeline by Astellas Pharma Inc., H2 2014 17 Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 18 Secondary Hyperparathyroidism - Pipeline by OPKO Health, Inc., H2 2014 19 Secondary Hyperparathyroidism - Pipeline by NPS Pharmaceuticals, Inc., H2 2014 20 Secondary Hyperparathyroidism - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2014 21 Assessment by Monotherapy Products, H2 2014 22 Number of Products by Stage and Target, H2 2014 24 Number of Products by Stage and Mechanism of Action, H2 2014 26 Number of Products by Stage and Route of Administration, H2 2014 28 Number of Products by Stage and Molecule Type, H2 2014 30 Secondary Hyperparathyroidism Therapeutics - Recent Pipeline Updates, H2 2014 52 Secondary Hyperparathyroidism - Dormant Projects, H2 2014 60
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.